Tag Archive for: Opdivo

Bristol Myers Squibb secured another late-phase immuno-oncology victory Wednesday, showing that the combination of Opdivo and Yervoy improved overall survival in a patient population served by rival checkpoint inhibitors from AstraZeneca and Roche.

Bristol Myers Squibb’s Opdivo was recently granted FDA approval in combination with cisplatin and gemcitabine as a first-line treatment for metastatic urothelial carcinoma. With this approval, Opdivo positions itself to compete with Merck & Co’s immune checkpoint inhibitor Keytruda in combination with Astellas and Pfizer’s Padcev, a nectin-4-directed antibody-drug conjugate, according to GlobalData.

Bristol Myers Squibb’s PD-1 blocker Opdivo (nivolumab) failed part B of the Phase III CheckMate-914 study, bearing no significant disease-free survival benefit for patients with localized renal cell carcinoma who are at high-risk of relapse after surgery.

The company is putting a stop to a trial investigating what it calls the Opdualag combination, a pairing of Opdivo (nivolumab) and relatlimab, in patients with microsatellite stable metastatic colorectal cancer.

The drug, to be sold under the brand name Augtyro, is set to compete in a crowded market for lung cancer treatments that includes Bristol Myers’ other cancer treatment Opdivo and rival cancer drugs from Roche, Merck, and AstraZeneca.

The new formulation of the drug that was tested in the trial used Halozyme Therapeutics’ (HALO.O) proprietary technology, which allows large volumes of Opdivo, currently administered intravenously, to be delivered as an injection under the skin.

Retiring BMS CEO Giovanni Caforio is handing off a company orders of magnitude different than it was at the beginning of his tenure.

The drug was being studied in patients with types of urothelial carcinoma who are eligible for cisplatin-based chemotherapy.

Data from a new head-to-head study showed BMS’ Opdivo induced better progression-free survival among Hodgkin’s lymphoma patients than Seagen’s Adcetris.

The series of direct-to-consumer oncology advertisements targeting patients with advanced kidney cancer (renal cell carcinoma) and their caregivers.